**eTable 2. Retreatment Cohort – Initial irAEs: Clinical Characteristics and Features**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Recurrent/New irAE** | **No subsequent irAE** | ***P* value** |
| No. of patients, No. (%) | 20 (52) | 18 (48) |  |
| Median age, years (range) | 64 (49-82) | 62 (50-83) | 0.73 |
| Sex, female, No. (%) | 8 (40) | 10 (55) | 0.51 |
| Smoking history, No. (%) |  |  | 0.17 |
| Yes | 19 (95) | 14 (79) |
| No | 1 (5) | 4 (21) |
| Histology, No. (%) |  |  | 0.34 |
| Adenocarcinoma | 10 (50) | 13 (72) |
| Squamous | 7 (35) | 4 (22) |
| LCNEC + NOS | 3 (15) | 1 (6) |
| Immunotherapy treatment data, No. (%) |  |  | 1.0 |
| Anti-PD-1 or Anti-PD-L1 | 13 (65) | 11 (61) |
| Combination | 7 (35) | 7 (39) |
| Line of therapy, No. (%) |  |  | 0.71 |
| First | 13 (65) | 12 (67) |
| Second | 6 (30) | 4 (22) |
| >=3 | 1 (5) | 2 (11) |
| Best overall response, No. (%) |  |  | 0.02 |
| CR or PR | 13 (65) | 5 (28) |
| SD or PD | 7 (35) | 13 (72) |
| Grade of irAE, No. (%) |  |  | 0.5 |
| Grades 1 or 2 | 12 (60) | 13 (72) |
| Grades 3 or 4 | 8 (40) | 5 (28) |
| Hospitalization, No. (%) | 7 (35) | 1 (6) | 0.04 |
| Steroids used, No. (%) |  |  | 1.0 |
| Intravenous | 2 (15) | 1 (8) |
| Oral | 12 (85) | 11 (92) |
| Steroids > 4 weeks, No. (%) | 7/14 (50) | 3/12 (25) | 0.46 |
| Treatment duration before initial irAE, No. (%) |  |  | 0.09 |
| < 90 days | 16 (79) | 9 (50) |
| ≥ 90 days | 4 (21) | 9 (50) |

NOTE. Data presented as No. (%) unless otherwise noted.

Abbreviations: LCNEC, large-cell neuroendocrine cancer; NOS, not otherwise specified carcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.